Tony Su (@ztonysu) 's Twitter Profile
Tony Su

@ztonysu

urology resident @brady_urology by way of @hopkinsmedicine & @yale. #WeTheNorth

ID: 1105589705377222656

calendar_today12-03-2019 22:01:41

143 Tweet

302 Followers

558 Following

Taibo (@taibo_li) 's Twitter Profile Photo

I am humbled and BEYOND EXCITED to have matched at my dream program The Johns Hopkins Brady Urological Institute I am deeply grateful for the past eight years of memorable experiences at Hopkins and look forward to training to become a surgeon scientist with so many amazing mentors and colleagues.

Ashish M. Kamat, MD, MBBS (@urodocash) 's Twitter Profile Photo

Our recent publication in European Urology Oncology demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC. A critical step forward in precision intravesical therapy.

Our recent publication in <a href="/EurUrolOncol/">European Urology Oncology</a> demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC.
A critical step forward in precision intravesical therapy.
Sandeep Gurram (@sandeepgurrammd) 's Twitter Profile Photo

Excited to share our work performed at National Cancer Institute addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! nejm.org/doi/full/10.10…

Excited to share our work performed at <a href="/theNCI/">National Cancer Institute</a> addressing needs of rare hereditary kidney cancer through bench to bedside work

Bevacizumab + erlotinib for #HLRCC assoc RCC
📍Response rate 72%
📍mPFS 21.1 mo

Thanks to the patients who supported the study!
nejm.org/doi/full/10.10…
JAMA Oncology (@jamaonc) 's Twitter Profile Photo

Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. ja.ma/45rVOSb Ivo Schoots

Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. ja.ma/45rVOSb <a href="/IvoSchootsNL/">Ivo Schoots</a>